Vanqua Bio presents Phase 1b data on GCase activator VQ-101 in Parkinson’s

Follow-up data presented at the American Academy of Neurology (AAN) 2026 annual meeting has provided further details on the development of VQ-101, an investigational once-daily oral drug for Parkinson's disease. We first reported on this therapy in October 2024 when the company initiated Phase 1b testing following promising safety results in healthy volunteers. VQ-101 is designed to address a common biological deficit in Parkinson’s: significantly reduced activity of the GCase enzyme. This enzyme is essential for processing cellular waste. When its activity drops—which occurs consistently in individuals with GBA gene mutations and frequently in those with non-genetic (idiopathic) Parkinson’s—toxic proteins can accumulate and damage dopamine-producing neurons. VQ-101 is an "allosteric activator" intended to bind to the enzyme and restore its function. The new data confirms that the trial has now moved from testing healthy volunteers to testing people living with the condition, including groups with and without the GBA genetic mutation. The key objective of this Phase 1b study was to determine if the drug, when taken daily as a pill, could cross the blood-brain barrier at levels high enough to achieve meaningful enzyme activation in humans. Key trial results presented at AAN 2026 The data indicates that VQ-101 was successful in hitting its intended biological target in the central nervous system of study participants: Significant enzyme activation: The trial confirmed that VQ-101 activated the GCase enzyme in a dose-dependent manner. While a 50% increase in activity is often cited as a threshold for potential therapeutic benefit, the higher doses used in this study achieved a median enzyme activation of greater than 75% in people with Parkinson’s. This is noteworthy as it essentially restores GCase function to the levels typically observed in individuals without the condition. Proven brain penetration: Analysis of the participants' cerebrospinal fluid (spinal fluid) confirmed that the drug achieved full penetrance into the central nervous system. This demonstrates that the medication is reaching the target brain cells at concentrations expected to be therapeutically effective. Favourable safety profile: In the single and multiple ascending dose groups, VQ-101 continued to show a very favourable safety and tolerability profile, with no serious adverse events reported by the participants. Looking ahead to longer-term data As the trial moves forward, participants from the main Phase 1b cohorts have had the option to join an "open-label extension." This allows them to continue taking VQ-101 for an extended period. Data from this extension, which includes participants who have now been on the therapy for several months, indicates that the safety profile remains consistent and that the enzyme activation is sustained over time. While these results are a necessary and positive milestone, showing that the drug safely interacts with the intended biological pathway in humans, it is important to remember that this study was not designed to measure symptom improvement or disease progression. The next critical stage of research will involve larger, longer-term clinical trials to determine if this level of GCase activation can slow down the development of Parkinson’s symptoms over time.